Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction

被引：20

作者：

Haug K.B.F. ^{[1
]}

Sharikabad M.N. ^{[1
]}

Kringen M.K. ^{[1
]}

Narum S. ^{[1
]}

Sjaatil S.T. ^{[1
]}

Johansen P.W. ^{[1
]}

Kierulf P. ^{[1
]}

Seljeflot I. ^{[2
]}

Arnesen H. ^{[2
]}

Brørs O. ^{[1
]}

机构：

[1] RandD, Department of Clinical Chemistry, Ulleval University Hospital, O407 Oslo

[2] Center for Clinical Research, Ulleval University Hospital, 0407 Oslo

来源：

Thrombosis Journal | / 6卷 / 1期

关键词：

Warfarin; International Normalize Ratio; Warfarin Dose; Warfarin Treatment; Warfarin Group;

D O I：

10.1186/1477-9560-6-7

中图分类号：

学科分类号：

摘要：

Background: Warfarin treatment has a narrow therapeutic range, requiring meticulous monitoring and dosage titration. Individual dosage requirement has recently partly been explained by genetic variation of the warfarin metabolizing enzyme CYP2C9 and the Vitamin K-activating enzyme VKORC1. In the WARIS-II study, comparing three different antithrombotic regimens after myocardial infarction, warfarin treatment reduced thrombotic events, but was associated with more frequent bleeding than use of acetylsalisylic acid (ASA) alone. Aims: The primary aim of the present study was to investigate the relation between genotypes of CYP2C9 and VKORC1 and warfarin maintenance dose in myocardial infarction. The secondary aim was to relate the genotypes to international normalized ratio (INR). Methods: Genotyping was performed in 212 myocardial infarction patients from the WARIS-II study by robotic isolation of DNA from EDTA whole blood (MagNa Pure LC) before PCR amplification (LightCycler) and melting point analysis. Results: The 420 C>T substitution of CYP2C9*2, the 1075 A>C substitution of CYP2C9*3 and the 1173 C>T substitution of VKORC1 had minor allele frequencies of, 11.3%, 5.7% and 36.6% respectively. Warfarin weekly dose varied between 17 mg and 74 mg among the patients. INR did not vary between genotypes. Warfarin dosage requirement was significantly associated with CYP2C9 and VKORC1 genotypes, treatment group and age. The VKORC1 genotype contributed 24.5% to the interindividual variation in warfarin dosage, whereas the combined CYP2C9 genotypes were only responsible for 7.2% of the dose variation. Conclusion: CYP2C9 and VKORC1 genotype frequencies in myocardial infarction patients appear similar to other patient groups and have similar impact on warfarin maintenance dose. © 2008 Haug et al; licensee BioMed Central Ltd.

引用

共 32 条

[1]

Drapkin A., Merskey C., Anticoagulant therapy after acute myocardial infarction. Relation of therapeutic benefit to patient's age, sex, and severity of infarction, Jama, 222, pp. 541-548, (1972)

[2]

Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction, Lancet, 343, pp. 499-503, (1994)

[3]

Smith P., Arnesen H., Holme I., The effect of warfarin on mortality and reinfarction after myocardial infarction, N Engl J Med, 323, pp. 147-152, (1990)

[4]

Asinger R.W., Mikell F.L., Elsperger J., Hodges M., Incidence of left-ventricular thrombosis after acute transmural myocardial infarction. Serial evaluation by two-dimensional echocardiography, N Engl J Med, 305, pp. 297-302, (1981)

[5]

Gottlieb L.K., Salem-Schatz S., Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice?, Arch Intern Med, 154, pp. 1945-1953, (1994)

[6]

Heneghan C., Alonso-Coello P., Garcia-Alamino J.M., Perera R., Meats E., Glasziou P., Self-monitoring of oral anticoagulation: A systematic review and meta-analysis, Lancet, 367, pp. 404-411, (2006)

[7]

Vecsler M., Loebstein R., Almog S., Kurnik D., Goldman B., Halkin H., Gak E., Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin, Thromb Haemost, 95, pp. 205-211, (2006)

[8]

Wadelius M., Chen L.Y., Downes K., Ghori J., Hunt S., Eriksson N., Wallerman O., Melhus H., Wadelius C., Bentley D., Deloukas P., Common VKORC1 and GGCX polymorphisms associated with warfarin dose, Pharmacogenomics J, 5, pp. 262-270, (2005)

[9]

Takahashi H., Wilkinson G.R., Nutescu E.A., Morita T., Ritchie M.D., Scordo M.G., Pengo V., Barban M., Padrini R., Ieiri I., Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans, Pharmacogenet Genomics, 16, pp. 101-110, (2006)

[10]

Rieder M.J., Reiner A.P., Gage B.F., Nickerson D.A., Eby C.S., McLeod H.L., Blough D.K., Thummel K.E., Veenstra D.L., Rettie A.E., Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose, N Engl J Med, 352, pp. 2285-2293, (2005)

← 1 2 3 4 →